TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04799574

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy activities
Description: Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy activities
Description: Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities.
Study: NCT03103412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00741988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: ixabepilone 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: ixabepilone 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
Study: NCT01400750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ciprofloxacin plus inhaled colistin
Description: oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBI
Description: tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
Study: NCT00215306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHARITÉ Artificial Disc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Interbody Fusion with BAK Cage
Study: NCT00117988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Study: NCT02444013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03517579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Collar Therapy Indicator (COTI)
Description: Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131.
Study: NCT03338218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte 6%
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ionolyte
Description: Solution for infusion
Study: NCT04344405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: control
Study: NCT02580487

Intervention type: PROCEDURE
Intervention: appendicectomy
Description: Appendix was removed either laparoscopically or open surgery

Intervention type: PROCEDURE
Intervention: appendicectomy
Description: Appendix was removed either laparoscopically or open surgery
Study: NCT03830008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
Study: NCT03136705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Nicotinamide tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Nicotinamide tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum Carbonate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum Carbonate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate Placebo
Description: Sugar pill manufactured to look like Lanthanum Carbonate tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanthanum Carbonate Placebo
Description: Sugar pill manufactured to look like Lanthanum Carbonate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Placebo
Description: Sugar pill manufactured to look like Nicotinamide tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Placebo
Description: Sugar pill manufactured to look like Nicotinamide tablet
Study: NCT03430245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelaShape III
Description: The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
Study: NCT03965988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: Docosahexaenoic acid
Study: NCT03854474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT04074135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Gallium DOTATATE
Description: 68-Gallium DOTATATE, to be used in yearly PET/CT research scans
Study: NCT03374306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine (0.01%)
Description: tropical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: tropical application
Study: NCT01370551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.03 mg, lyophylized lactobacillus
Description: Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
Study: NCT04083378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Therapy
Description: Undergo standard of care ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Therapy
Description: Undergo standard of care ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Therapy
Description: Undergo software-aided imaging (Morfeus)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02413970

Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® UAS System
Description: This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
Study: NCT03996291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film coated tablet Route of administration: Oral
Study: NCT03461991

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrahigh resolution Spectral Domain OCT
Description: A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Study: NCT01172782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
Study: NCT04241276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: 45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: 125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study: NCT02056769

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: Quantitative CT Perfusion imaging
Study: NCT01561469

Intervention type: DRUG
Intervention: Linezolid
Description: Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.

Intervention type: DRUG
Intervention: Vancomycin
Description: Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
Study: NCT02314195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin re-uptake inhibitor
Description: A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin re-uptake inhibitor
Description: A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: 12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
Study: NCT04194827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adalimumab serum trough concentration
Description: Dose reduction based on adalimumab serum trough concentration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Disease activity
Description: Dose reduction based on adalimumab diseas activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab
Study: NCT03207347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
Study: NCT01761149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
Study: NCT01558167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Rituximab, Lenalidomide
Description: Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose
Study: NCT00572559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 1 gram IV every 12 hours for 7 to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
Study: NCT00469118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRX9000™
Description: Nonsurgical spinal decompression
Study: NCT02814266

Intervention type: OTHER
Group type: OTHER
Intervention: difficult intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.

Intervention type: OTHER
Group type: OTHER
Intervention: difficult intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.

Intervention type: OTHER
Group type: OTHER
Intervention: easy intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.

Intervention type: OTHER
Group type: OTHER
Intervention: easy intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
Study: NCT00925730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Study: NCT03313128

Intervention type: OTHER
Intervention: Sanitation
Description: Improved sanitation facility
Study: NCT03317639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour Change Wheel model guided intervention
Description: Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
Study: NCT03904199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive long-acting insulin and/or rapid-acting insulin per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Study: NCT03321955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziconotide 100 MCG(microgram)/ML Intrathecal Solution
Description: Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
Study: NCT02371304

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
Study: NCT00643279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronicle Implantable Hemodynamic Monitor
Description: Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
Study: NCT04029779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-PRF
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study: NCT01811420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemomechanical Caries Removal
Description: Chemomechanical Caries Removal Using A Papain-Based Gel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: Dental caries removal using rotatory instrument
Study: NCT02987387

Intervention type: DEVICE
Intervention: SAPIEN XT THV
Description: SAPIEN XT THV will be implanted in the pulmonic position.
Study: NCT02410187

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy (chemotherapy, hormon therapy, target therapy etc)
Description: Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic therapy (chemotherapy, hormon therapy, target therapy etc)
Description: Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative RT
Description: fraction size of RT = \< 3 Gy